Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials | Cardiovascular Diabetology

Ethical Approval and Consent to Participate

The study was approved by the appropriate national and institutional regulatory and ethics boards and all patients provided written informed consent.

Consent to publish

Not applicable.

Competing Interests

MOW has served on advisory boards or lectured for MSD, Lilly, Novo Nordisk and Sanofi, and has hosted a professional regional meeting sponsored by Lilly, Rubin Medical, Sanofi, Novartis and Novo Nordisk. BC reports advice for Amgen, Boehringer Ingelheim, Corvia, Myokardia, Novartis. MV has received research grant or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa and Roche Diagnostics, speaker engagement at Novartis and Roche Diagnostics, and participates in clinical endpoint committees for studies sponsored by Galmed and Novartis. MP reports the following disclosures: Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson, Lilly, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics , Theravance. MZ reports to Novartis as a member of the steering committees for both PARADIGM-HF and PARAGON-HF. JR reports the following disclosures: Consultant Novartis, Aventis, AstraZeneca, Bayer, Myokardia/BMS. KS reports fees from Astrazeneca, Boerhinger-Mannheim, Novartis. ML is a full-time employee of Novartis Pharmaceuticals. SJS has received research grants from Actelion, AstraZeneca, Corvia, Novartis and Pfizer; and has served advisory fees at Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards, Eisai, Ionis, Ironwood, Merck, MyoKardia, Novartisizer, Prothena, Pf , Regeneron, Sanofi, Shifamed, Tenax and United Therapeutics. MAP Notifies Research Grant to Novartis Institution; is a member of the PARAGON-HF steering committee and study chair of PARADISE-MI; reports advisory for AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, Corvidia, DalCor, GlaxoSmithKline, NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has shares in DalCor and Peerbridge. JJVM reports payments to his employer, Glasgow University, for his work on clinical trials, consulting and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer, Theracos and Personal Payments: Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Ionis, Lupine, ProAdWise Communications, Sun Pharmaceuticals, Servier. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Res Sanofi Pasteur , Theracos, and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myocardia, Novartis , Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta. JCW, RR and AJ report no disclosures.

Leave a Comment

Your email address will not be published.